Performance Evaluation of Lateral Flow Assays for Coronavirus Disease-19 Serology

Ochola, Lucy; Ogongo, Paul; Mungai, Samuel; Gitaka, Jesse; Suliman, Sara

doi:10.1016/j.cll.2021.10.005

Cited by 10 publications

(14 citation statements)

References 170 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lateral flow tests (LFTs) based on SARS-CoV-2 antigen (Ag) have become an affordable and scalable method of providing mass surveillance and testing for an individual’s viral status ( 1 – 3 ). The reliability of such testing devices is crucial for providing rapid health information to the user and maintaining public trust in their value.…”

Section: Observationmentioning

confidence: 99%

See 1 more Smart Citation

Stability of the COVID-19 At-Home Test after Exposure to Extreme Temperatures

2023

View full text Add to dashboard Cite

show abstract

Section: Observationmentioning

confidence: 99%

“…The reliability of such testing devices is crucial for providing rapid health information to the user and maintaining public trust in their value. Consequently, they must be able to maintain performance in a variety of handling and storage conditions, including varying temperatures and climates ( 3 ).…”

Section: Observationmentioning

confidence: 99%

Stability of the COVID-19 At-Home Test after Exposure to Extreme Temperatures

2023

View full text Add to dashboard Cite

show abstract

“…In regions where other beta-coronaviruses are present, their N-terminal domain of the N antigen is highly conserved, which may cause N-LFIAs to give false-positive results and/or fail to detect true early sensitization [ 98 ]. LFIA targeting the S antigens does not distinguish between vaccine- and infection-induced antibodies [ 99 ] ( Figure 3 A). The incorporation of the ACE2 receptor as an immobilized protein in the test pad assay line enhanced the LFIA sensitivity.…”

Section: Lateral Flow Immunoassay Evolution In the Pandemicmentioning

confidence: 99%

Challenges in the Detection of SARS-CoV-2: Evolution of the Lateral Flow Immunoassay as a Valuable Tool for Viral Diagnosis

et al. 2022

View full text Add to dashboard Cite

SARS-CoV-2 is an emerging infectious disease of zoonotic origin that caused the coronavirus disease in late 2019 and triggered a pandemic that has severely affected human health and caused millions of deaths. Early and massive diagnosis of SARS-CoV-2 infected patients is the key to preventing the spread of the virus and controlling the outbreak. Lateral flow immunoassays (LFIA) are the simplest biosensors. These devices are clinical diagnostic tools that can detect various analytes, including viruses and antibodies, with high sensitivity and specificity. This review summarizes the advantages, limitations, and evolution of LFIA during the SARS-CoV-2 pandemic and the challenges of improving these diagnostic devices.

show abstract

“…8,9 The importance of onsite fast testing was highlighted during the SARS-CoV-2 pandemic, where LFDs were used to monitor and prevent viral spread. 10,11 Interleukin-6 (IL-6) increases within a few minutes of stimulus and has a half-life of 30 min, which is ideal for neonatal sepsis diagnosis. 6 This work investigates and compares the performance of large selenium nanoparticles (SeNPs) to that of commercial standard 40 nm gold nanoparticles (AuNPs) in the detection of IL-6 in a LFD.…”

Section: Introductionmentioning

confidence: 99%

Effect of Selenium Nanoparticle Size on IL-6 Detection Sensitivity in a Lateral Flow Device

Bradley

Coleman

Courtney³

et al. 2023

ACS Omega

View full text Add to dashboard Cite

Sepsis is the body’s response to an infection. Existing diagnostic testing equipment is not available in primary care settings and requires long waiting times. Lateral flow devices (LFDs) could be employed in point-of-care (POC) settings for sepsis detection; however, they currently lack the required sensitivity. Herein, LFDs are constructed using 150–310 nm sized selenium nanoparticles (SeNPs) and are compared to commercial 40 nm gold nanoparticles (AuNPs) for the detection of the sepsis biomarker interleukin-6 (IL-6). Both 310 and 150 nm SeNPs reported a lower limit of detection (LOD) than 40 nm AuNPs (0.1 ng/mL compared to 1 ng/mL), although at the cost of test line visual intensity. This is to our knowledge the first use of larger SeNPs (>100 nm) in LFDs and the first comparison of the effect of the size of SeNPs on assay sensitivity in this context. The results herein demonstrate that large SeNPs are viable alternatives to existing commercial labels, with the potential for higher sensitivity than standard 40 nm AuNPs.

show abstract

Performance Evaluation of Lateral Flow Assays for Coronavirus Disease-19 Serology

Cited by 10 publications

References 170 publications

Stability of the COVID-19 At-Home Test after Exposure to Extreme Temperatures

Stability of the COVID-19 At-Home Test after Exposure to Extreme Temperatures

Challenges in the Detection of SARS-CoV-2: Evolution of the Lateral Flow Immunoassay as a Valuable Tool for Viral Diagnosis

Effect of Selenium Nanoparticle Size on IL-6 Detection Sensitivity in a Lateral Flow Device

Contact Info

Product

Resources

About